Hamershlag Private Capital Management (HPCM) has made a venture investment in Patho Care, structured as an acquisition and recapitalisation valued at $150.15m.

This deal, involving newly issued common stock and cash through PathoCare Holdings, aims to provide Patho Care with the necessary resources to expand its operations and establish a solid market position.

The strategic investment by HPCM claims to be indicative of its commitment to fostering healthcare solutions while seeking substantial returns for its investors.

It also allowed for the repayment of Patho Care's current financial obligations.

Patho Care’s Raman spectroscopy-based testing platform, which holds 17 patents, is expected to innovate diagnostics testing further.

With this funding, Patho Care aims to expand its service range, ‘improve’ operational efficiencies and drive ‘innovation’ within the diagnostics testing sector.

This move marks a pivotal addition to HPCM's investment portfolio. Both entities are said to be focused on a smooth transition and the continuation of quality service for all of PathoCare’s stakeholders.

HPCM chairman Mychal Jefferson said: “Patho Care is a distinguished leader in healthcare diagnostics through the utilisation of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries.

“Our commitment to delivering transformative value through innovative investments underscores our confidence in PathoCare’s vision and capabilities.”

A subsidiary of PathoCare Holdings, Patho Care ‘specialises’ in point-of-care testing (POCT) devices that are programmable, digital, reusable, and accurate and are tailored for the identification and characterisation of respiratory bacterial or viral infections.

The system's adaptive AI claims to increase the accuracy of outcomes through spectral diagnostic and laboratory-developed test testing confirmation models.